FDA Grants Priority Review for TZIELD (Teplizumab) Supplement
The FDA has granted priority review status for the supplemental Biologics License Application (BLA) for TZIELD (teplizumab) submitted by Provention Bio.
Asset / Drug
Drug and asset intelligence for TZIELD with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has granted priority review for the supplemental application of TZIELD (Teplizumab) by Provention Bio.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.